FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4293485753> ?p ?o ?g. }

• W4293485753 abstract "Background: Mucopolysaccharidosis II (MPS II; Hunter syndrome; OMIM 309900) is a rare, X-linked, lysosomal storage disease caused by deficient iduronate-2-sulfatase activity. Accumulation of glycosaminoglycans results in multisystemic disease manifestations, which may include central nervous system involvement and cognitive impairment (CI). Patients with MPS II experience a high disease burden, leading to extensive healthcare resource utilization (HRU) and reduced quality of life. Objectives: This study aimed to assess the impact of timing of enzyme replacement therapy (ERT) initiation and CI status on the clinical characteristics and HRU of patients with MPS II. Methods: A retrospective medical chart review of 140 male patients who received a diagnosis of MPS II between 1997 and 2017 was performed at 19 US sites; data on disease manifestations and HRU stratified by age at ERT initiation or CI status were analyzed for the full study population and a subgroup of patients who received a diagnosis of MPS II before the age of 6 years. Results: In patients initiating ERT before 3 years of age, there was a trend toward lower symptom burden and HRU compared with patients who initiated ERT at an older age. Evaluation of developmental and behavioral signs and symptoms in the full study population showed that communication delay (70.0% of patients), cognitive delay (62.1%), behavioral problems (52.9%), and toileting delay (50.0%) were particularly common; earliest documented signs and symptoms were motor delay (median [range] age at first documentation: 4.2 [0.9-18.7] years) and behavioral problems (4.4 [0.6-13.7] years). Patients with CI generally experienced greater symptom burden and higher HRU than those without CI, with the most notable differences documented for communication and toileting delays. Formal cognitive testing was documented in <30% of cognitively impaired patients diagnosed with MPS II before the age of 6 years. Conclusions: Our findings reinforce previous recommendations for ERT to be initiated early to maximally benefit patients with MPS II, especially those younger than 3 years old. Cognitively impaired patients experience a particularly high disease burden and HRU. Patient care could be improved with early cognitive assessments and the development of treatments that address cognitive decline." @default.
• W4293485753 created "2022-08-29" @default.
• W4293485753 creator A5000620336 @default.
• W4293485753 creator A5023054981 @default.
• W4293485753 creator A5025381791 @default.
• W4293485753 creator A5075846136 @default.
• W4293485753 creator A5078823223 @default.
• W4293485753 creator A5083867875 @default.
• W4293485753 date "2022-08-29" @default.
• W4293485753 modified "2023-09-30" @default.
• W4293485753 title "Impact of the Timing of Enzyme Replacement Therapy Initiation and Cognitive Impairment Status on Outcomes for Patients with Mucopolysaccharidosis II (MPS II) in the United States: A Retrospective Chart Review" @default.
• W4293485753 cites W1598400863 @default.
• W4293485753 cites W1950828885 @default.
• W4293485753 cites W1968258454 @default.
• W4293485753 cites W1973635706 @default.
• W4293485753 cites W1989295722 @default.
• W4293485753 cites W1993027304 @default.
• W4293485753 cites W1997831257 @default.
• W4293485753 cites W2001925765 @default.
• W4293485753 cites W2009904895 @default.
• W4293485753 cites W2020409398 @default.
• W4293485753 cites W2026477204 @default.
• W4293485753 cites W2027292988 @default.
• W4293485753 cites W2034511507 @default.
• W4293485753 cites W2049736899 @default.
• W4293485753 cites W2092327321 @default.
• W4293485753 cites W2094903408 @default.
• W4293485753 cites W2103457363 @default.
• W4293485753 cites W2113874233 @default.
• W4293485753 cites W2115034909 @default.
• W4293485753 cites W2117030035 @default.
• W4293485753 cites W2117500144 @default.
• W4293485753 cites W2134704141 @default.
• W4293485753 cites W2153536356 @default.
• W4293485753 cites W2313552595 @default.
• W4293485753 cites W2314508473 @default.
• W4293485753 cites W2325546716 @default.
• W4293485753 cites W2617895008 @default.
• W4293485753 cites W2745716847 @default.
• W4293485753 cites W2754304291 @default.
• W4293485753 cites W2761204945 @default.
• W4293485753 cites W2913603103 @default.
• W4293485753 cites W2966275708 @default.
• W4293485753 cites W2970843865 @default.
• W4293485753 cites W3006540808 @default.
• W4293485753 cites W3030202434 @default.
• W4293485753 cites W3082017038 @default.
• W4293485753 cites W3090225575 @default.
• W4293485753 cites W3126243062 @default.
• W4293485753 cites W3133295428 @default.
• W4293485753 cites W3133565909 @default.
• W4293485753 cites W3135263704 @default.
• W4293485753 cites W3165686226 @default.
• W4293485753 cites W4214612938 @default.
• W4293485753 cites W4280515815 @default.
• W4293485753 doi "https://doi.org/10.36469/001c.36540" @default.
• W4293485753 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/36168594" @default.
• W4293485753 hasPublicationYear "2022" @default.
• W4293485753 type Work @default.
• W4293485753 citedByCount "0" @default.
• W4293485753 crossrefType "journal-article" @default.
• W4293485753 hasAuthorship W4293485753A5000620336 @default.
• W4293485753 hasAuthorship W4293485753A5023054981 @default.
• W4293485753 hasAuthorship W4293485753A5025381791 @default.
• W4293485753 hasAuthorship W4293485753A5075846136 @default.
• W4293485753 hasAuthorship W4293485753A5078823223 @default.
• W4293485753 hasAuthorship W4293485753A5083867875 @default.
• W4293485753 hasBestOaLocation W42934857531 @default.
• W4293485753 hasConcept C126322002 @default.
• W4293485753 hasConcept C167135981 @default.
• W4293485753 hasConcept C187212893 @default.
• W4293485753 hasConcept C195910791 @default.
• W4293485753 hasConcept C2776225084 @default.
• W4293485753 hasConcept C2779134260 @default.
• W4293485753 hasConcept C2779416428 @default.
• W4293485753 hasConcept C2779969927 @default.
• W4293485753 hasConcept C2908647359 @default.
• W4293485753 hasConcept C2910638406 @default.
• W4293485753 hasConcept C71924100 @default.
• W4293485753 hasConcept C99454951 @default.
• W4293485753 hasConceptScore W4293485753C126322002 @default.
• W4293485753 hasConceptScore W4293485753C167135981 @default.
• W4293485753 hasConceptScore W4293485753C187212893 @default.
• W4293485753 hasConceptScore W4293485753C195910791 @default.
• W4293485753 hasConceptScore W4293485753C2776225084 @default.
• W4293485753 hasConceptScore W4293485753C2779134260 @default.
• W4293485753 hasConceptScore W4293485753C2779416428 @default.
• W4293485753 hasConceptScore W4293485753C2779969927 @default.
• W4293485753 hasConceptScore W4293485753C2908647359 @default.
• W4293485753 hasConceptScore W4293485753C2910638406 @default.
• W4293485753 hasConceptScore W4293485753C71924100 @default.
• W4293485753 hasConceptScore W4293485753C99454951 @default.
• W4293485753 hasIssue "2" @default.
• W4293485753 hasLocation W42934857531 @default.
• W4293485753 hasLocation W42934857532 @default.
• W4293485753 hasLocation W42934857533 @default.
• W4293485753 hasLocation W42934857534 @default.
• W4293485753 hasOpenAccess W4293485753 @default.
• W4293485753 hasPrimaryLocation W42934857531 @default.
• W4293485753 hasRelatedWork W1572142576 @default.

• next